ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0006

NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0294

Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0483

Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0659

Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0405

Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0739

One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0367

Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0535

Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0400

Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0716

Outcomes of COVID-19 in Patients with ANCA-Associated Vasculitis (AAV)

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0708

Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0253

Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0093

Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure

SLE – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0438

Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0323

Pain Prevalence and Factors Associated with Pain Levels in Patients with Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].